Enrollment milestone advances the FDA Fast Track-designated program toward data review and analysis TORONTO — Vasomune Therapeutics Inc. (“Vasomune”), a clinical-stage biopharmaceutical company developing medicines that target endotheliopathy and vascular leak, today announced the completion of patient enrollment in AV001-004 (NCT05123755), its randomized, double-blind, placebo-controlled Phase…
In der Corona-Pandemie verdiente Biontech Milliarden - damit ist es vorbei. Das Unternehmen muss sparen, baut Personal ab. Nun ist klar, dass an drei Standorten die Tore endgültig schließen.
The US says it is unable to support a major global text on pandemic prevention and preparedness put forward at UN general assembly The United States government’s decision to block a major global…
